ClinicalTrials.gg
CompletedNCT03922321Updated Jan 24, 2022Results posted

Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

A Phase 2 interventional study of RVT-1401 in Graves' Ophthalmopathy, sponsored by Immunovant Sciences GmbH. Completed at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-24.

Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to evaluate safety, tolerability, and pharmacodynamic parameters of RVT-1401 in graves' ophthalmopathy (GO) patients.

02

Conditions studied

  • Graves' Ophthalmopathy

Browse trials for

Keywords

  • IMVT-1401
  • Graves' Orbitopathy
  • Thyroid Eye Disease
03

In context

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

This study's enrollment of 7 is below the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.

Browse Graves Ophthalmopathy studies →

Lead sponsor

Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age.
  2. Clinical diagnosis of Graves' disease with hyperthyroidism associated with active, moderate to severe GO with a Clinical Activity Score (CAS) ≥ 4 for the most severely affected eye at Screening (on the 7-item scale) and Baseline (on the 10-item scale).
  3. Onset of active GO within 9 months of screening.
  4. Moderate-to-severe active GO (not sight-threatening but has an appreciable impact on daily life), usually associated with one or more of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, proptosis ≥ 3 mm above normal for race and gender, and/or inconstant or constant diplopia.
  5. Other, more specific inclusion criteria are defined in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Use of any (intravenous [IV] or oral) with a cumulative dose equivalent to ≥ 1 g of methylprednisolone for the treatment of GO within 3 weeks prior to Screening.
  2. Use of rituximab, tocilizumab, or any monoclonal antibody for immunomodulation within the past 9 months prior to Baseline.
  3. Total IgG level \< 6g/L at Screening.
  4. \<1500 cells/mm3 at Screening.
  5. Participants with decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months at Screening.
  6. Previous orbital irradiation or surgery for GO.
  7. Other, more specific exclusion criteria are defined in the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    RVT-1401

    RVT-1401 680 milligrams (mg) weekly for two weeks followed by 340 mg weekly for four weeks, administered subcutaneously

    Drug: RVT-1401

Interventions

  • RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment Period

    AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug and on or before the date of the last dose of study drug + 42 days, or had no recorded start date and the stop date was in between the date of the first dose and the last dose of study drug + 42 days. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

    Time frame: from Baseline up to Week 6

  2. Number of Participants With Clinically Significant Findings Related to Vital Signs

    Clinical significance was determined by the investigator.

    Time frame: up to Week 18

  3. Number of Participants With a Change From Normal Physical Examination Findings at Baseline to Abnormal Physical Examination Findings at the End of the Study

    Abnormality was determined by the investigator.

    Time frame: up to Week 18

  4. Number of Participants With Clinically Significant Findings Related to Electrocardiograms (ECGs)

    Clinical significance was determined by the investigator.

    Time frame: up to Week 18

  5. Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels

    The serum levels of total IgG and IgG subclasses (1-4) were determined. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7, Week 6 and 7 combined) minus the Baseline value, divided by the Baseline value x 100. A negative percent change from Baseline represents clinical improvement.

    Time frame: Baseline; Week 7; Week 6 and 7 combined

  6. Mean Change From Baseline in Levels of Anti-thyroid-stimulating Hormone Receptor (Anti-TSHR) Antibodies at Week 7

    The serum levels of anti-TSHR antibodies were determined. Change from Baseline was calculated as the Week 7 value minus the Baseline value. A negative change from Baseline represents clinical improvement.

    Time frame: Baseline; Week 7

Secondary outcomes

  1. Mean Change From Baseline in Proptosis in the Study Eye and Non-study Eye at Week 7

    The study eye was defined as the most severely affected eye at the Baseline visit. In the event that both eyes were affected the same, the right eye was deemed as the study eye. Participants who did not achieve a proptosis response were censored at the date of their last proptosis measurement that occurred in both eyes. Change from Baseline was calculated as the Week 7 value minus the Baseline value. A negative change from Baseline represents clinical improvement.

    Time frame: Baseline; Week 7

  2. Number of Participants With an Overall Proptosis Response

    Proptosis responders were defined as participants with a ≥2 mm reduction in study eye without deterioration (≥2 mm increase) in the fellow eye. Participants who did not achieve a proptosis response were censored at the date of their last proptosis measurement that occurred in both eyes.

    Time frame: Up to Week 18

  3. Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401

    Pharmacokinetic (PK) parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.

    Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8

  4. Maximum Concentration (Cmax) of RVT-1401

    PK parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.

    Time frame: Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8

  5. Serum Concentration at the End of the Dosing Interval (Ctrough) of RVT-1401

    Time frame: Week 2, Week 3, Week 4, Week 5, Week 6 Day 36, and Week 7

  6. Number of Participants With Anti-RVT-1401 Antibody and Confirmed Anti-RVT-1401 Antibody at Week 7

    The serum levels of anti-RVT-1401 antibodies were determined. In the initial analysis the samples with responses equal to or above the plate-specific cut-point were identified as potentially positive while those below the cut-point were considered negative. These potentially positive samples were reanalyzed in confirmatory assay. Samples with percent inhibition greater than or equal to the confirmatory cut-point were considered confirmed positive and those below were considered negative.

    Time frame: Week 7

07

Results

Posted Jan 24, 2022
Limitations and caveats
The PK parameters of AUC0-168h and Cmax were not estimated because of sparse PK sampling schedule.

Participant flow

Participant flow — Overall Study
MilestoneRVT-1401
Started7
Completed5
Not completed2
Withdrew: Participant moved1
Withdrew: Unable to come to site due to covid 191

Outcome measures

PrimaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment Period

AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug and on or before the date of the last dose of study drug + 42 days, or had no recorded start date and the stop date was in between the date of the first dose and the last dose of study drug + 42 days. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

Time frame:
from Baseline up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment Period
ParticipantsRVT-1401
TEAEs7
SAEs0
Treatment-related AEs6
Deaths0
PrimaryNumber of Participants With Clinically Significant Findings Related to Vital Signs

Clinical significance was determined by the investigator.

Time frame:
up to Week 18
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings Related to Vital Signs
ParticipantsRVT-1401
Number of Participants With Clinically Significant Findings Related to Vital Signs0
PrimaryNumber of Participants With a Change From Normal Physical Examination Findings at Baseline to Abnormal Physical Examination Findings at the End of the Study

Abnormality was determined by the investigator.

Time frame:
up to Week 18
Reported as:
Count of participants · Participants
Number of Participants With a Change From Normal Physical Examination Findings at Baseline to Abnormal Physical Examination Findings at the End of the Study
ParticipantsRVT-1401
Number of Participants With a Change From Normal Physical Examination Findings at Baseline to Abnormal Physical Examination Findings at the End of the Study0
PrimaryNumber of Participants With Clinically Significant Findings Related to Electrocardiograms (ECGs)

Clinical significance was determined by the investigator.

Time frame:
up to Week 18
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Findings Related to Electrocardiograms (ECGs)
ParticipantsRVT-1401
Number of Participants With Clinically Significant Findings Related to Electrocardiograms (ECGs)0
PrimaryPercent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels

The serum levels of total IgG and IgG subclasses (1-4) were determined. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7, Week 6 and 7 combined) minus the Baseline value, divided by the Baseline value x 100. A negative percent change from Baseline represents clinical improvement.

Time frame:
Baseline; Week 7; Week 6 and 7 combined
Reported as:
Mean · Percent change
Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels
Percent changeRVT-1401
Total IgG (Week 6 and 7 combined)-65.00 ± 10.78
Total IgG (Week 7)-64.83 ± 17.65
IgG1 (Week 7)-67.16 ± 18.89
IgG2 (Week 7)-56.91 ± 24.66
IgG3 (Week 7)-70.05 ± 21.71
IgG4 (Week 7)-61.28 ± 16.25
PrimaryMean Change From Baseline in Levels of Anti-thyroid-stimulating Hormone Receptor (Anti-TSHR) Antibodies at Week 7

The serum levels of anti-TSHR antibodies were determined. Change from Baseline was calculated as the Week 7 value minus the Baseline value. A negative change from Baseline represents clinical improvement.

Time frame:
Baseline; Week 7
Reported as:
Mean · international units/milliliter (IU/mL)
Mean Change From Baseline in Levels of Anti-thyroid-stimulating Hormone Receptor (Anti-TSHR) Antibodies at Week 7
international units/milliliter (IU/mL)RVT-1401
Baseline19.72 ± 15.073
Week 7-10.59 ± 9.827
SecondaryMean Change From Baseline in Proptosis in the Study Eye and Non-study Eye at Week 7

The study eye was defined as the most severely affected eye at the Baseline visit. In the event that both eyes were affected the same, the right eye was deemed as the study eye. Participants who did not achieve a proptosis response were censored at the date of their last proptosis measurement that occurred in both eyes. Change from Baseline was calculated as the Week 7 value minus the Baseline value. A negative change from Baseline represents clinical improvement.

Time frame:
Baseline; Week 7
Reported as:
Mean · millimeter (mm)
Mean Change From Baseline in Proptosis in the Study Eye and Non-study Eye at Week 7
millimeter (mm)RVT-1401
Baseline, study eye23.1 ± 3.34
Change from Baseline to Week 7, study eye-1.25 ± 1.50
Baseline, non-study eye21.9 ± 3.63
Change from Baseline to Week 7, non-study eye-1.25 ± 0.96
SecondaryNumber of Participants With an Overall Proptosis Response

Proptosis responders were defined as participants with a ≥2 mm reduction in study eye without deterioration (≥2 mm increase) in the fellow eye. Participants who did not achieve a proptosis response were censored at the date of their last proptosis measurement that occurred in both eyes.

Time frame:
Up to Week 18
Reported as:
Count of participants · Participants
Number of Participants With an Overall Proptosis Response
ParticipantsRVT-1401
Number of Participants With an Overall Proptosis Response3
SecondaryArea Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401

Pharmacokinetic (PK) parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.

Time frame:
Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) of RVT-1401

PK parameters were not estimated because the sparse PK sampling schedule did not allow for accurate estimates of these parameters.

Time frame:
Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8

No measurements were reported for this outcome.

SecondarySerum Concentration at the End of the Dosing Interval (Ctrough) of RVT-1401
Time frame:
Week 2, Week 3, Week 4, Week 5, Week 6 Day 36, and Week 7
Reported as:
Mean · mg/L
Serum Concentration at the End of the Dosing Interval (Ctrough) of RVT-1401
mg/LRVT-1401
Week 24.018 ± 5.9584
Week 312.075 ± 14.6431
Week 41.284 ± 2.3063
Week 50.167 ± 0.1682
Week 6 Day 360.660 ± 1.5529
Week 70.077 ± 0.0381
SecondaryNumber of Participants With Anti-RVT-1401 Antibody and Confirmed Anti-RVT-1401 Antibody at Week 7

The serum levels of anti-RVT-1401 antibodies were determined. In the initial analysis the samples with responses equal to or above the plate-specific cut-point were identified as potentially positive while those below the cut-point were considered negative. These potentially positive samples were reanalyzed in confirmatory assay. Samples with percent inhibition greater than or equal to the confirmatory cut-point were considered confirmed positive and those below were considered negative.

Time frame:
Week 7
Reported as:
Count of participants · Participants
Number of Participants With Anti-RVT-1401 Antibody and Confirmed Anti-RVT-1401 Antibody at Week 7
ParticipantsRVT-1401
Initial analysis: negative anti-RVT-1401 antibody5
Initial analysis: potentially positive anti-RVT-1401 antibody2
Confirmed analysis: negative anti-RVT-1401 antibody2

Adverse events

Collected over from Baseline up to Week 18. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RVT-14010/7 (0%)0/7 (0%)7/7 (100%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventRVT-1401
Lacrimation increasedEye disorders2/7
FatigueGeneral disorders2/7
DizzinessNervous system disorders2/7
PalpitationsCardiac disorders1/7
Eye swellingEye disorders1/7
Ocular hyperaemiaEye disorders1/7
Swelling of eyelidEye disorders1/7
KeratopathyEye disorders1/7
Eye painEye disorders1/7
Eye irritationEye disorders1/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RVT-1401
Mean56.7 ± 14.9
Sex: Female, Male
Sex: Female, Male(Participants)RVT-1401
Female4
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RVT-1401
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RVT-1401
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported0
Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels
Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels(grams per liter (g/L))RVT-1401
IgG11.29 ± 1.71
IgG15.11 ± 1.11
IgG23.74 ± 0.96
IgG30.61 ± 0.35
IgG40.49 ± 0.34
08

Study locations

4 sites
  • UBC/VGH Eye Care Center
    Vancouver, British Columbia V5Z 3N9, Canada
  • Toronto Retina Institute
    North York, Ontario M3C 0G9, Canada
  • University of Ottwa Eye Institute
    Ottawa, Ontario K1H 8L6, Canada
  • CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont
    Montreal, Quebec H1T 2M4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Feb 2020, 10 months.

Results were first posted in Jan 2022, 1 year 10 months after primary completion. A results delay was requested in May 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 19, 2019
StartActual
Apr 22, 2019
Primary completionActual
Feb 29, 2020
CompletionActual
May 21, 2020
Results delay requested
May 10, 2021
Results first posted
Jan 24, 2022
Last update
Jan 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03922321
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
Apr 19, 2019
Start date
Apr 22, 2019
Primary completion
Feb 29, 2020
Completion
May 21, 2020
Results posted
Jan 24, 2022
Last update
Jan 24, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion